1. Aizarani, Nadim, Saviano, Antonio, Mailly, Laurent, Baumert, Thomas F, Grün, Dominic. 2019. A human liver cell atlas reveals heterogeneity and epithelial progenitors. In Nature, 572, 199-204. doi:10.1038/s41586-019-1373-2. https://pubmed.ncbi.nlm.nih.gov/31292543/
2. Shvartsur, Anna, Bonavida, Benjamin. . Trop2 and its overexpression in cancers: regulation and clinical/therapeutic implications. In Genes & cancer, 6, 84-105. doi:. https://pubmed.ncbi.nlm.nih.gov/26000093/
3. Vidula, Neelima, Yau, Christina, Rugo, Hope. 2022. Trophoblast Cell Surface Antigen 2 gene (TACSTD2) expression in primary breast cancer. In Breast cancer research and treatment, 194, 569-575. doi:10.1007/s10549-022-06660-x. https://pubmed.ncbi.nlm.nih.gov/35789445/
4. Sperger, Jamie M, Helzer, Kyle T, Stahlfeld, Charlotte N, Dehm, Scott M, Lang, Joshua M. . Expression and Therapeutic Targeting of TROP-2 in Treatment-Resistant Prostate Cancer. In Clinical cancer research : an official journal of the American Association for Cancer Research, 29, 2324-2335. doi:10.1158/1078-0432.CCR-22-1305. https://pubmed.ncbi.nlm.nih.gov/36939530/
5. Bahlinger, Veronika, Branz, Annalena, Strissel, Pamela L, Hartmann, Arndt, Eckstein, Markus. 2024. Associations of TACSTD2/TROP2 and NECTIN-4/NECTIN-4 with molecular subtypes, PD-L1 expression, and FGFR3 mutational status in two advanced urothelial bladder cancer cohorts. In Histopathology, 84, 863-876. doi:10.1111/his.15130. https://pubmed.ncbi.nlm.nih.gov/38196202/
6. Morgenstern-Kaplan, Dan, Kareff, Samuel A, Trabolsi, Asaad, Vanderwalde, Ari M, Lopes, Gilberto. . Genomic, immunologic, and prognostic associations of TROP2 (TACSTD2) expression in solid tumors. In The oncologist, 29, e1480-e1491. doi:10.1093/oncolo/oyae168. https://pubmed.ncbi.nlm.nih.gov/38986529/
7. Alehabib, Elham, Jamshidi, Javad, Ghaedi, Hamid, Mohajerani, Fatemeh, Darvish, Hossein. 2017. Novel Mutations in TACSTD2 Gene in Families with Gelatinous Drop-like Corneal Dystrophy (GDLD). In International journal of molecular and cellular medicine, 6, 204-211. doi:10.22088/BUMS.6.4.204. https://pubmed.ncbi.nlm.nih.gov/29988226/
8. Cardillo, Thomas M, Govindan, Serengulam V, Sharkey, Robert M, Chang, Chien-Hsing, Goldenberg, David M. 2015. Sacituzumab Govitecan (IMMU-132), an Anti-Trop-2/SN-38 Antibody-Drug Conjugate: Characterization and Efficacy in Pancreatic, Gastric, and Other Cancers. In Bioconjugate chemistry, 26, 919-31. doi:10.1021/acs.bioconjchem.5b00223. https://pubmed.ncbi.nlm.nih.gov/25915780/
9. Deng, Zebin, Dong, Zheng, Wang, Yinhuai, Liu, Jiachen, Deng, Fei. 2024. Identification of TACSTD2 as novel therapeutic targets for cisplatin-induced acute kidney injury by multi-omics data integration. In Human genetics, 143, 1061-1080. doi:10.1007/s00439-024-02641-w. https://pubmed.ncbi.nlm.nih.gov/38369676/
智鼠故事 
